Open menuDiscover

---

HealthTop NewsWeatherEntertainmentSportsFinanceLifestyleDiningTravelAutos

AI Drug Candidate Might Change The Case For Investing In Sanofi (ENXTPA:SAN)

On 15 October 2026, Recursion Pharmaceuticals announced that Sanofi had optioned the first development candidate from their AI-driven immunology collaboration. This triggered a $10 million milestone payment and added a potential first in class oral small molecule to Sanofi’s pipeline. Sanofi also signed a Letter of Intent with the pan Canadian Pharmaceutical Alliance for Dupixent across four additional indications. This underscores how the drug’s expanding reach in dermatology and...Simply Wall St

Establishment Labs Stock Has The Bull Case Changed After FDA Implant Size Approval?

Establishment Labs Holdings reported that the FDA has approved an expanded range of Motiva SmoothSilk Round and Ergonomix breast implant sizes for U.S. use, adding 28 new options across Mini, Demi and Full profiles, including volumes as small as 105 cc, with commercial availability planned before the end of 2026. The wider size matrix gives surgeons more precise combinations of base, projection and volume. This can support procedure customization, address a broader mix of patient anatomies...Simply Wall St

Nurix Therapeutics (NRIX) Could Be 20% Below Fair Value After Roche Fueled Profit Turn

Nurix Therapeutics (NRIX) is back in focus after a sharp swing to profitability in its fiscal third quarter, helped by a large Roche collaboration payment and growing momentum behind its bexobrutideg program. The latest surge in Nurix Therapeutics reflects that story catching more attention, with a 1-day share price return of 5.41% and a 7-day share price move of 12.34% around the earnings and Roche milestones. At the same time, the 1-year total shareholder return of 148.75% and very large...Simply Wall St

Legend Biotech (LEGN) Following FDA Clearance For LB2501 Has Its Value Story Back In Focus

Legend Biotech (NasdaqGS:LEGN) is back in focus after the U.S. Food and Drug Administration cleared its IND for LB2501, an in vivo CAR-T candidate targeting CD19 and CD20 in relapsed or refractory B-cell malignancies. Legend Biotech’s shares have reacted quickly to the FDA update, with a 1-day share price return of 3.99% and a 30-day share price return of 12.05%. However, this momentum comes off a weaker base, given the 1-year total shareholder return declined 38.81% and the 3-year total...Simply Wall St

Is Sonova Holding (SWX:SOON) Fairly Valued Following Its New AI Hearing Product Launches?

Sonova Holding (SWX:SOON) has put its AI-heavy Roger On Sphere microphone and Integro CI cochlear implant system in the spotlight at the EUHA congress, giving investors fresh product news to assess. That EUHA showcase lands at a time when Sonova Holding’s share price has climbed to CHF274.2. The company has recorded a strong 30-day share price return of 20.16% and a 90-day gain of 33.50%, while the 1-year total shareholder return of 28.51% points to momentum that has strengthened in recent...Simply Wall St